Compare Stocks: ORMP, FDMT, CTMX, and NVCT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTMX CytomX Therapeutics	$3.17 -3.8%	$3.47	$1.90 ▼ $8.21	$689.65M	2.14	4.77 million shs	3.73 million shs
FDMT 4D Molecular Therapeutics	$13.89 +5.5%	$12.64	$6.47 ▼ $16.93	$768.72M	2.74	825,793 shs	688,682 shs
NVCT Nuvectis Pharma	$23.66 -1.4%	$21.08	$5.55 ▼ $29.27	$772.88M	-0.26	168,535 shs	113,488 shs
ORMP Oramed Pharmaceuticals	$4.69 +0.6%	$4.48	$2.09 ▼ $5.47	$195.10M	1.19	229,427 shs	96,136 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTMX CytomX Therapeutics	0.00%	-11.32%	-2.08%	+8.22%	+64.50%
FDMT 4D Molecular Therapeutics	0.00%	-12.02%	+8.04%	+42.84%	+93.39%
NVCT Nuvectis Pharma	0.00%	-2.04%	+26.53%	+115.16%	+289.45%
ORMP Oramed Pharmaceuticals	0.00%	-6.99%	+4.02%	+21.35%	+93.36%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTMX CytomX Therapeutics	$3.17 -3.8%	$3.47	$1.90 ▼ $8.21	$689.65M	2.14	4.77 million shs	3.73 million shs
FDMT 4D Molecular Therapeutics	$13.89 +5.5%	$12.64	$6.47 ▼ $16.93	$768.72M	2.74	825,793 shs	688,682 shs
NVCT Nuvectis Pharma	$23.66 -1.4%	$21.08	$5.55 ▼ $29.27	$772.88M	-0.26	168,535 shs	113,488 shs
ORMP Oramed Pharmaceuticals	$4.69 +0.6%	$4.48	$2.09 ▼ $5.47	$195.10M	1.19	229,427 shs	96,136 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTMX CytomX Therapeutics	0.00%	-11.32%	-2.08%	+8.22%	+64.50%
FDMT 4D Molecular Therapeutics	0.00%	-12.02%	+8.04%	+42.84%	+93.39%
NVCT Nuvectis Pharma	0.00%	-2.04%	+26.53%	+115.16%	+289.45%
ORMP Oramed Pharmaceuticals	0.00%	-6.99%	+4.02%	+21.35%	+93.36%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTMX CytomX Therapeutics	2.83	Moderate Buy	$11.90	265.59% Upside
FDMT 4D Molecular Therapeutics	2.82	Moderate Buy	$28.56	103.18% Upside
NVCT Nuvectis Pharma	2.80	Moderate Buy	$36.25	53.90% Upside
ORMP Oramed Pharmaceuticals	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest ORMP, FDMT, CTMX, and NVCT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/14/2026	FDMT 4D Molecular Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$20.00
9/8/2026	ORMP Oramed Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C+)
9/4/2026	NVCT Nuvectis Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/1/2026	NVCT Nuvectis Pharma	Loop Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$40.00
9/1/2026	NVCT Nuvectis Pharma	Lucid Cap Mkts Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/24/2026	NVCT Nuvectis Pharma	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight
8/20/2026	NVCT Nuvectis Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/19/2026	CTMX CytomX Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/17/2026	FDMT 4D Molecular Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/13/2026	FDMT 4D Molecular Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$32.00
8/13/2026	CTMX CytomX Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$12.00 ➝ $11.00

(Data available from 9/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTMX CytomX Therapeutics	$76.20M	9.31	N/A	N/A	$0.58 per share	5.61
FDMT 4D Molecular Therapeutics	$85.21M	9.11	N/A	N/A	$8.85 per share	1.59
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	$0.72 per share	N/A
ORMP Oramed Pharmaceuticals	$2M	98.20	$0.09 per share	51.37	$5.02 per share	0.94

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTMX CytomX Therapeutics	-$17.37M	-$0.50	N/A	N/A	N/A	-435.21%	-38.46%	-30.33%	11/5/2026 (Estimated)
FDMT 4D Molecular Therapeutics	-$140.11M	-$2.63	N/A	N/A	N/A	-194.74%	-41.33%	-35.90%	11/10/2026 (Estimated)
NVCT Nuvectis Pharma	-$26.44M	-$1.31	N/A	N/A	N/A	N/A	-184.25%	-105.24%	11/3/2026 (Estimated)
ORMP Oramed Pharmaceuticals	$64.05M	$4.12	1.15	N/A	N/A	N/A	-5.17%	-4.54%	11/12/2026 (Estimated)

Latest ORMP, FDMT, CTMX, and NVCT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	FDMT 4D Molecular Therapeutics	-$1.02	-$1.04	-$0.02	-$1.04	$3.62 million	$3.78 million
8/10/2026	Q2 2026	ORMP Oramed Pharmaceuticals	$0.43	-$0.09	-$0.52	$1.84	N/A	N/A
8/6/2026	Q2 2026	CTMX CytomX Therapeutics	-$0.0771	-$0.09	-$0.0129	-$0.09	$12.39 million	$1.42 million
8/4/2026	Q2 2026	NVCT Nuvectis Pharma	-$0.2620	-$0.30	-$0.0380	-$0.30	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
FDMT 4D Molecular Therapeutics	N/A	N/A	N/A	N/A	N/A
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	N/A
ORMP Oramed Pharmaceuticals	$0.25	5.30%	N/A	6.07%	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTMX CytomX Therapeutics	N/A	9.36	9.36
FDMT 4D Molecular Therapeutics	0.05	8.03	8.03
NVCT Nuvectis Pharma	N/A	1.68	1.68
ORMP Oramed Pharmaceuticals	N/A	4.98	4.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTMX CytomX Therapeutics	67.77%
FDMT 4D Molecular Therapeutics	99.27%
NVCT Nuvectis Pharma	96.77%
ORMP Oramed Pharmaceuticals	12.73%

Insider Ownership

Company	Insider Ownership
CTMX CytomX Therapeutics	3.80%
FDMT 4D Molecular Therapeutics	7.90%
NVCT Nuvectis Pharma	28.55%
ORMP Oramed Pharmaceuticals	20.77%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTMX CytomX Therapeutics	69	217.90 million	209.62 million	Optionable
FDMT 4D Molecular Therapeutics	196	55.24 million	50.88 million	Optionable
NVCT Nuvectis Pharma	13	32.64 million	23.32 million	Not Optionable
ORMP Oramed Pharmaceuticals	10	41.60 million	32.96 million	Optionable

ORMP, FDMT, CTMX, and NVCT Headlines

Recent News About These Companies

Zacks Research Has Pessimistic Outlook of ORMP Q3 Earnings

September 4, 2026 | americanbankingnews.com

Q3 EPS Estimate for Oramed Pharmaceuticals Cut by Analyst

September 2, 2026 | marketbeat.com

Oramed Pharmaceuticals (NASDAQ:ORMP) Upgraded by Wall Street Zen to Buy Rating

August 15, 2026 | marketbeat.com

Oramed: Q2 Earnings Snapshot

August 11, 2026 | chron.com

Insider Selling: Oramed Pharmaceuticals (NASDAQ:ORMP) CFO Sells $330,853.60 in Stock

July 3, 2026 | insidertrades.com

Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet

June 25, 2026 | prnewswire.com

ORMP: View inclusion in Russell indexes as positive that could raise awareness in investment community

June 18, 2026 | msn.com

Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes

June 17, 2026 | prnewswire.com

ORMP: Strategically acquiring interests in medtech & technology companies

June 8, 2026 | msn.com

Oramed Pharmaceuticals: 'Hold' On Oral Insulin Drug Failure Pivot And New Strategic Investment Direction

May 22, 2026 | seekingalpha.com

Oramed Pharmaceuticals Inc.

May 18, 2026 | marketwatch.com

Oramed Pharmaceuticals Delays Quarterly SEC Filing

May 15, 2026 | tipranks.com

Oramed Pharmaceuticals Earnings Estimates, EPS & Revenue | NASDAQ:ORMP

May 15, 2026 | benzinga.com

Oramed Pharmaceuticals Incorporated

April 15, 2026 | edition.cnn.com

Oramed Pharmaceuticals (ORMP) price target increased by 92.31% to 6.38

March 27, 2026 | msn.com

Oramed: Q4 Earnings Snapshot

March 26, 2026 | stamfordadvocate.comS

Lifeward Ltd.: Lifeward Successfully Closes on Strategic Partnership with Oramed

March 26, 2026 | finanznachrichten.de

Lifeward Partners with Oramed to Enhance Biotech Portfolio and Drive Path to Profitability

March 13, 2026 | quiverquant.comQ

Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company

March 13, 2026 | globenewswire.com

Oramed Pharmaceuticals Inc.: Oramed and Lifeward Announce Strategic Transaction

January 13, 2026 | finanznachrichten.de

Oramed and Lifeward Announce Strategic Transaction

January 13, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORMP, FDMT, CTMX, and NVCT Company Descriptions

CytomX Therapeutics NASDAQ:CTMX

$3.16 -0.13 (-3.80%)

As of 03:34 PM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

4D Molecular Therapeutics NASDAQ:FDMT

$13.89 +0.72 (+5.47%)

As of 03:34 PM Eastern

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

Nuvectis Pharma NASDAQ:NVCT

$23.66 -0.33 (-1.38%)

As of 03:34 PM Eastern

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Oramed Pharmaceuticals NASDAQ:ORMP

$4.69 +0.03 (+0.64%)

As of 03:33 PM Eastern

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ORMP, FDMT, CTMX, and NVCT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ORMP, FDMT, CTMX, and NVCT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ORMP, FDMT, CTMX, and NVCT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORMP, FDMT, CTMX, and NVCT Company Descriptions

CytomX Therapeutics NASDAQ:CTMX

4D Molecular Therapeutics NASDAQ:FDMT

Nuvectis Pharma NASDAQ:NVCT

Oramed Pharmaceuticals NASDAQ:ORMP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ORMP, FDMT, CTMX, and NVCT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ORMP, FDMT, CTMX, and NVCT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ORMP, FDMT, CTMX, and NVCT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORMP, FDMT, CTMX, and NVCT Company Descriptions

CytomX Therapeutics NASDAQ:CTMX

4D Molecular Therapeutics NASDAQ:FDMT

Nuvectis Pharma NASDAQ:NVCT

Oramed Pharmaceuticals NASDAQ:ORMP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools